Morquio A can lead to a variety of complications, such as problems with the heart, lungs, muscles, and bones. These complications can reduce endurance, which may make regular activities more difficult.

  • Heart complications

    Examples: Thickening and/or narrowing of valves, valve insufficiency

  • Breathing complications

    Examples: Sleep apnea, respiratory infections, restricted lungs and airways, complications with sinuses

  • Muscle and skeletal complications

    Examples: Overly flexible joints, joint pain, hip dysplasia, knock-knees, reduced height


Reduced endurance

  • Difficulty with regular daily activities
  • Limited mobility 
  • Reduced quality of life
  •  

Image

Heart complications

Examples: Thickening and/or narrowing of valves, valve insufficiency

Image

Breathing complications

Examples: Sleep apnea, respiratory infections, restricted lungs and airways, complications with sinuses

Image

Muscle and skeletal complications

Examples: Overly flexible joints, joint pain, hip dysplasia, knock-knees, reduced height


Reduced endurance

  • Difficulty with regular daily activities
  • Limited mobility 
  • Reduced quality of life
  •  

How is endurance measured?

Endurance can be measured using a test called the 6-minute walk test (6MWT), which measures how far a person can walk in 6 minutes. 

  • For people who have difficulty walking, the timed 25-foot walk test (T25FWT) can also be used to measure endurance

Medical researchers have used the 6MWT to show that people with Morquio A can have significantly less endurance than people who do not have Morquio A. 

6-minute walk test



6-minute walk test



Back Title

Endurance can be measured using a test called the 6-minute walk test (6MWT).

LEARN MORE

Timed 25-foot walk test



Timed 25-foot walk test



Back Title

The timed 25-foot walk test (T25FWT) can be used to measure endurance in patients who have difficulty walking.

LEARN MORE

INDICATION
VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

IMPORTANT SAFETY INFORMATION

Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM® (elosulfase alfa) infusions. Typical signs of anaphylaxis include cough, rash, throat tightness, hives, flushing, changes in skin color, low blood pressure, shortness of breath, chest pain, and gastrointestinal symptoms such as nausea, abdominal pain, retching, and vomiting. Contact your doctor or get medical help right away if these symptoms occur during or after VIMIZIM infusions. If you have a respiratory illness, you may be at risk for a sudden worsening of your condition, and you may require additional monitoring.

VIMIZIM is a prescription medicine. Before treatment with VIMIZIM, it is important to discuss your medical history with your doctor. Tell your doctor if you are sick or taking any medication and if you are allergic to any medicines. Also tell your doctor if you are pregnant, planning to become pregnant, or are a nursing mother. Your doctor will decide if VIMIZIM is right for you. If you have questions or would like more information about VIMIZIM, contact your doctor.

Anaphylaxis can occur during any VIMIZIM infusion and up to three hours after any infusion, and hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion.

Serious and severe reactions can happen with VIMIZIM treatment, including life-threatening allergic reactions (anaphylaxis), hives, swelling, cough, shortness of breath, and flushing. You should receive medication such as antihistamines before VIMIZIM infusions to reduce the risk of reactions. If a reaction occurs, the infusion should be slowed or stopped and you may be given additional medication. If a severe reaction occurs, the infusion should be stopped immediately and you will receive appropriate medical treatment.

If you have acute febrile or respiratory illness at the time of VIMIZIM infusion you may be at higher risk of life-threatening complications from hypersensitivity reactions. If you use supplemental oxygen or continuous positive airway pressure (CPAP) you should have it available during your infusion in the event of a sudden reaction, or extreme drowsiness/sleep from antihistamines.

Spinal cord damage may occur due to the natural MPS IVA disease process. Signs of spinal cord injury include back pain, numbness and paralysis, and loss of bladder and bowel control. Contact your doctor immediately if you develop any of these symptoms.

The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, call BioMarin RareConnections at 1-866-906-6100.

Please see full Prescribing Information, including important warning.